Home > Insider Trading > Filing (0001140361-13-034586)

Filing Details

Accession Number:: 0001140361-13-034586
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-08-29 16:34:05
Reporting Period:: 2013-08-27

Filing Date:: 2013-08-29
Accepted Time:: 2013-08-29 16:34:05
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1311596	Regado Biosciences Inc	RGDO	Pharmaceutical Preparations (2834)	030422069

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1435388	Jefferson B. Clark	120 Mountain View Boulevard Basking Ridge NJ 07920		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock, Par Value $0.001 Per Share	Acquisiton	2013-08-27	145,411	$0.00	164,722	No	4	C	Indirect	See Footnote 7
Common Stock, Par Value $0.001 Per Share	Acquisiton	2013-08-27	87,325	$0.00	252,047	No	4	C	Indirect	See Footnote 7
Common Stock, Par Value $0.001 Per Share	Acquisiton	2013-08-27	133,067	$0.00	385,114	No	4	C	Indirect	See Footnote 7
Common Stock, Par Value $0.001 Per Share	Acquisiton	2013-08-27	321,973	$0.00	707,087	No	4	C	Indirect	See Footnote 7
Common Stock, Par Value $0.001 Per Share	Acquisiton	2013-08-27	48,362	$0.00	755,449	No	4	C	Indirect	See Footnote 7
Common Stock, Par Value $0.001 Per Share	Acquisiton	2013-08-27	359,310	$4.00	1,114,759	No	4	P	Indirect	See Footnote 8

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	See Footnote 7
No	4	C	Indirect	See Footnote 7
No	4	C	Indirect	See Footnote 7
No	4	C	Indirect	See Footnote 7
No	4	C	Indirect	See Footnote 7
No	4	P	Indirect	See Footnote 8

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock, Par Value $0.001 Per Share	Stock Option (right to buy)	Acquisiton	2013-08-27	17,964	$0.00	17,964	$4.00
Common Stock, Par Value $0.001 Per Share	Series A Preferred Stock	Disposition	2013-08-27	2,428,367	$0.00	145,411	$0.00
Common Stock, Par Value $0.001 Per Share	Series B Preferred Stock	Disposition	2013-08-27	1,458,333	$0.00	87,325	$0.00
Common Stock, Par Value $0.001 Per Share	Series C Preferred Stock	Disposition	2013-08-27	2,222,222	$0.00	133,067	$0.00
Common Stock, Par Value $0.001 Per Share	Series D Preferred Stock	Acquisiton	2013-08-27	5,376,964	$0.00	321,973	$0.00
Common Stock, Par Value $0.001 Per Share	Series E Preferred Stock	Disposition	2013-08-27	807,652	$0.00	48,362	$0.00

Remaning Holdings	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
17,964	2023-08-27	No	4	A	Direct
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect
0		No	4	C	Indirect

Footnotes

100% of the shares underlying the option will vest on the one-year anniversary of the date of grant.
The shares of Series A Preferred Stock had no expiration date and automatically converted upon the consummation of the initial public offering of Regado Biosciences, Inc. (the "Company") at a conversion ratio of 1 share of Series A Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
The shares of Series B Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series B Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
The shares of Series C Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series C Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
The shares of Series D Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series D Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
The shares of Series E Preferred Stock had no expiration date and automatically converted upon the consummation of the Company's initial public offering at a conversion ratio of 1 share of Series E Preferred Stock to 0.05988024 shares of common stock, for no additional consideration.
Except as noted in footnote 8 of this Form 4, the reportable securities are directly held by Aurora Ventures IV, LLC ("Aurora IV"). The Reporting Person is the manager of A.V. Management IV, L.L.C., the managing member of Aurora IV, and may be deemed to share voting and investment power. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
The reportable securities are directly held by Aurora Ventures V, L.P ("Aurora V"). The Reporting Person is the manager of A.V. Management V, L.L.C., the managing member of Aurora V, and may be deemed to share voting and investment power. The Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report is not an admission that he is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.